Citius Pharmaceuticals, through its majority-owned subsidiary Citius Oncology, reported preliminary shipment and institutional order data for LYMPHIR during the fiscal fourth quarter of 2026. These results represent the first period of full commercial operations following the achievement of nationwide sales force coverage in August.
Key Highlights
- LYMPHIR shipments to U.S. wholesalers reached 792 units, a 120% sequential increase from 360 units in the third quarter.
- Institutional adoption expanded to 54 centers to date, compared to 44 centers reported in mid-August.
- Prescribing centers ordered a total of 950 LYMPHIR vials from wholesalers during the quarter, reflecting steady demand growth.